When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results–these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
When we looked at the pre-treatment creatinine data, we found that African Americans were more likely to have abnormal results and white patients were more likely to have normal results—these differences were statistically significant, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.
Transcript
What did you find in your study of African American patients with AML with abnormal kidney tests?
So, when we looked at the pre-treatment creatinine data, and creatinine measures your kidney function, we found that African Americans were more likely to have abnormal results and white patients are more likely to have normal results—these differences were statistically significant. Additionally, when we looked at creatinine clearance data, again, a measure for kidney function, African Americans again had worse results than the white patient population. Again, suggesting that their kidney function is indeed worse than the white patient population. So, across the full cohort, 56% of the patients had some sort of renal dysfunction; but this proportion was higher among African Americans–63% of which had some sort of renal function abnormality that could have potentially excluded them from a clinical trial, but our outcomes suggest that minor renal dysfunction is not associated with clinical outcomes. Therefore, this might not be a reason alone to be excluding patients from clinical trials.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More